Eesti - eesti - Ravimiamet

accord healthcare b.v. - traneksaamhape - süstelahus - 100mg 1ml 10ml 5tk; 100mg 1ml 10ml 1tk; 100mg 1ml 5ml 5tk; 100mg 1ml 5ml 1tk; 100mg 1ml 10ml 10tk; 100mg 1ml 5ml 10tk

Eesti - eesti - Ravimiamet

baxter holding b.v. - traneksaamhape - süste-/infusioonilahus - 100mg 1ml 10ml 10tk; 100mg 1ml 5ml 10tk; 100mg 1ml 5ml 5tk; 100mg 1ml 10ml 5tk

Eesti - eesti - Ravimiamet

fresenius kabi polska sp. z o.o. - traneksaamhape - infusioonilahus - 10mg 1ml 100ml 20tk; 10mg 1ml 100ml 40tk

Eesti - eesti - Ravimiamet

haupt pharma wülfing gmbh - traneksaamhape - süste-/infusioonilahus - 100mg 1ml 5ml 5tk

Eesti - eesti - Ravimiamet

meda ab - traneksaamhape - õhukese polümeerikattega tablett - 500mg 20tk; 500mg 50tk; 500mg 100tk

Eesti - eesti - Ravimiamet

medochemie limited - traneksaamhape - süstelahus - 100mg 1ml 5ml 10tk; 100mg 1ml 10ml 10tk

Eesti - eesti - Ravimiamet

pfizer europe ma eeig - traneksaamhape - süstelahus - 100mg 1ml 5ml 10tk

Eesti - eesti - Ravimiamet

ideal trade links uab - traneksaamhape - õhukese polümeerikattega tablett - 500mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - imatiniib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatiniib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. välja arvatud äsja diagnoositud kroonilise faasi cml, ei ole kontrollitud uuringud, mis näitab kliiniline kasu või suurenenud ellujäämise eest need haigused. .

Eesti - eesti - Ravimiamet

accord healthcare b.v. - metotreksaat - süstelahus - 25mg 1ml 2ml 1tk